Ceftazidime
Ceftazidime
Ceftazidime
, Ermita, 1000 Manila Student Nurse: Pauline M. Basa Patients Name: CEFTAZIDIME Pharmacologic Action: Third-generation cephalosporin; Bind to the bacterial cell wallmembrane, causing cell death. Therapeutic Effect: Anti-infective; Bactericidal action against susctible bacteria. Spectrum: Similar to that of second-generation cephalosporins, but activity against staphylococci is less, whereas activity against gram-negative pathogens is greater, even for organisms resistant to first- and second-generation agents. Notable is increased action against: Enterobacter, Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, Neisseria gonorrhea, Citrobacter, Morganella, Proteus, Providencia, Serratia, Moraxella catarrhalis, Borrelia burgdorferi. Has activity against Neisseria meningitidis. Has enhanced activity against Pseudomonas aeruginosa. Not active against methicillin-resistance staphylococci or enterococci. Indications: Treatment of the following infections caused by susceptible organisms: Skin & skin structure infections, Urinary and gynecologic infections, Respiratory tract infections. Meningitis and bone/joint infections. Intra-abdominal infections and septicemia. Febrile neutropenia. Contraindications: Hypersensitivity to cephalosporins; Serious hypersensitivity to penicillins. Precautions: Renal impairment (decreased dosing/increased dosing interval recommended if CCr 50ml/min); History of GI disease, especially colitis; Geri: Dosage adjustment due to age-related in renal function may be necessary; Pregnancy and lactation (have been used safely). Adverse Reactions/Side Effects: CNS seizures (high doses), headache. GI pseudomembranous colitis, diarrhea, nausea, vomiting, cramps. Derm rashes, urticaria. Hema agranulocytosis, eosinophilia, hemolytic anemia, lymphocytosis, neutropenia, thrombocytopenia, thrombocytosis. GU hematuria, vaginal moniliasis. Local pain at IM site, phlebitis at IV site. Misc allergic reactions including anaphylaxis & serum sickness, superinfection. Interactions: [Drug-Drug] Concurrent use of loop diuretics or nephrotoxic agents including aminoglycosides may risk of nephrotoxicity. Nursing Implications: - Assess for infection (VS; wound appearance, sputum, urine, stool;WBC)at beg. of & throughout therapy. Obtain specimens for c/s before initiating therapy. 1st dose may be given before receiving results. - Before initiating therapy, obtain a hx to determine previous use of and reactions to penicillins or cephalosporins. Persons with a negative history of penicillin sensitivity may still have an allergic response. - Observe patient for signs and symptoms of anaphylaxis (rash, pruritus, laryngeal edema, wheezing). Discontinue drug and notify physician or other health care professional immediately if these symptoms occur. Keep epinephrine, an antihistamine, and resuscitation equipment close by in the event of an anaphylactic reaction. - Lab Test Considerations: May cause (+) results for Coombs test in patients receiving high doses or in neonates whose mothers were given cephalosporins before delivery. May cause serum AST, ALT, alkaline phosphatase, bilirubin, LDH, BUN, and creatinine. May rarely cause leukopenia, neutropenia, agranulocytosis, thrombocytopenia, eosinophilia, lymphocytosis, and thrombocytosis. - PO:Administer around the clock, on full or empty stomach (with food may minimize GI irritation). Shake oral susp. well. IM:Reconstitute IM doses with sterile or bacteriostatic water for injection or 0.9% NaCl for injection. May be diluted with lidocaine to minimize injection discomfort. Inject deep into a well-developed muscle mass;massage well. IV:Monitor site frequently for phlebitis (pain, redness, swelling), change sites q48-72hrs to prevent. If aminoglycosides are administered concurrently, administer in separate sites, if possible, at least 1 hr apart. If 2nd site is unavailable, flush lines bet. meds. - Direct IV: Dilute cephalosporins in at least 1 g/10 ml. Rate: Administer slowly over 35 min. Intermittent Infusion: Diluent: Reconstituted solution may be further diluted in at least 1 g/10ml of 0.9%NaCl, D5W, D10W, dextrose/saline combinations, or LR. Dilutioncauses CO2 to forminside vial, resulting in positive pressure; vialmay require venting after dissolution to preserve sterility of vial. Not required with L -arginine formulation (Ceptaz). Solution may appear yellow to amber; darkening does not alter potency. Solution is stable for 18 hr at roomtemperature and 7 days if refrigerated. Concentration: 40 mg/ ml. Rate: Administer over 1530 min. Ward/Bed no.: Date of assignment: